920282-10-6Relevant academic research and scientific papers
INHIBITORS OF RAF KINASES
-
Paragraph 00515-00517, (2021/04/30)
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose
Futatsugi, Kentaro,Smith, Aaron C.,Tu, Meihua,Raymer, Brian,Ahn, Kay,Coffey, Steven B.,Dowling, Matthew S.,Fernando, Dilinie P.,Gutierrez, Jemy A.,Huard, Kim,Jasti, Jayasankar,Kalgutkar, Amit S.,Knafels, John D.,Pandit, Jayvardhan,Parris, Kevin D.,Perez, Sylvie,Pfefferkorn, Jeffrey A.,Price, David A.,Ryder, Tim,Shavnya, Andre,Stock, Ingrid A.,Tsai, Andy S.,Tesz, Gregory J.,Thuma, Benjamin A.,Weng, Yan,Wisniewska, Hanna M.,Xing, Gang,Zhou, Jun,Magee, Thomas V.
, p. 13546 - 13560 (2021/01/01)
Increased fructose consumption and its subsequent metabolism have been implicated in metabolic disorders such as nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH) and insulin resistance. Ketohexokinase (KHK) converts fructose to fructose-1
NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
-
Page/Page column 117, (2020/01/08)
The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
